The late phase of preconditioning and its natural clinical application--gene therapy
about
The evolving concept of physiological ischemia training vs. ischemia preconditioningProtection from doxorubicin-induced cardiomyopathy using the modified anthracycline N-benzyladriamycin-14-valerate (AD 198).Novel therapeutic strategies for ischemic heart diseaseRole of microRNAs in cardiac preconditioningPreemptive conditioning of the swine heart by H11 kinase/Hsp22 provides cardiac protection through inducible nitric oxide synthase.Protective effects of remote ischemic preconditioning in rat hindlimb on ischemia- reperfusion injury.Second window of preconditioning normalizes palmitate use for oxidation and improves function during low-flow ischaemia.Role of Mitogen-Activated Protein Kinases in Myocardial Ischemia-Reperfusion Injury during Heart TransplantationAngiotensin-converting enzyme inhibition and food restriction restore delayed preconditioning in diabetic mice.Protective ischaemia in patients: preconditioning and postconditioning.Repetitive myocardial ischemia promotes coronary growth in the adult mammalian heart.Loss of cardioprotection with ageing.Gene transfer of inducible nitric oxide synthase affords cardioprotection by upregulating heme oxygenase-1 via a nuclear factor-{kappa}B-dependent pathway.Hydrogen sulfide-mediated myocardial pre- and post-conditioning.Genetics and genomics of ischemic tolerance: focus on cardiac and cerebral ischemic preconditioning.Repeated ischaemic preconditioning: a novel therapeutic intervention and potential underlying mechanisms.Exercise-Induced Cardioprotection and the Therapeutic Potential of RIPC.Gene therapy for myocardial infarction-associated congestive heart failure: how far have we got?Gene transfer as a strategy to achieve permanent cardioprotection II: rAAV-mediated gene therapy with heme oxygenase-1 limits infarct size 1 year later without adverse functional consequences.Gene transfer as a strategy to achieve permanent cardioprotection I: rAAV-mediated gene therapy with inducible nitric oxide synthase limits infarct size 1 year later without adverse functional consequences.Microarray expression analysis in delayed cardioprotection: the effect of exercise, AICAR, or metformin and the possible role of AMP-activated protein kinase (AMPK).Treatment with placental growth factor attenuates myocardial ischemia/reperfusion injury
P2860
Q26776276-25131811-6C97-4158-8245-2C45D65454E9Q34214717-FF0DA26E-9A86-4FC4-A68E-DE1F9341BC6CQ34276258-A7E34DB3-822D-4F3D-B824-67267E1B872DQ34503344-8C6C9AA7-8B85-44C5-ACB8-42B51AAC7908Q34784422-4BDE76B9-D874-4BDC-98AA-C087BB3AD8DEQ35139302-2C1572E2-BDAE-4273-8736-5A5D2919EB8FQ35538209-A89BCEE9-459D-423B-A95C-DC7183A48CB5Q35864123-82523B77-D595-4880-9970-809AA1726423Q36688050-8A7EC403-1113-46A6-9A24-7A452889506CQ37240955-54385BC2-EE37-4FCE-ADE6-365AF0F54F5BQ37328790-ED9C2F5E-5973-4CA4-934C-584526CD5798Q37379567-6ABA2D46-2A5B-4795-80EB-1AF3BF9EECE2Q37401916-5F4B4572-64C1-4CC2-B7FA-BF46BF583F59Q37849578-4A7B9FBA-8038-41F7-828F-C227ED2C1606Q38061499-45179F60-2771-4753-B63E-C8CA1637A437Q38771646-CD84EC4C-0F57-4ECB-AF2E-B139FB465E8EQ39385316-D13739D0-CE78-4862-BB1C-C789C263FB3CQ40014132-B1030686-DCD7-4DDF-B4C0-24BA58D411B6Q40257549-E02076EE-DED1-46FB-98FA-EE26E08A88C7Q40258000-E921B08D-5CDD-4308-8E16-3EE1103A8FD2Q51545583-F54FFF98-290D-406F-BB25-88ED09863D34Q58744453-5A7F8C38-0547-4B4E-A2FB-1B2541AE9BBC
P2860
The late phase of preconditioning and its natural clinical application--gene therapy
description
2007 nî lūn-bûn
@nan
2007 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
name
The late phase of preconditioning and its natural clinical application--gene therapy
@ast
The late phase of preconditioning and its natural clinical application--gene therapy
@en
The late phase of preconditioning and its natural clinical application--gene therapy
@nl
type
label
The late phase of preconditioning and its natural clinical application--gene therapy
@ast
The late phase of preconditioning and its natural clinical application--gene therapy
@en
The late phase of preconditioning and its natural clinical application--gene therapy
@nl
prefLabel
The late phase of preconditioning and its natural clinical application--gene therapy
@ast
The late phase of preconditioning and its natural clinical application--gene therapy
@en
The late phase of preconditioning and its natural clinical application--gene therapy
@nl
P2093
P2860
P1476
The late phase of preconditioning and its natural clinical application--gene therapy
@en
P2093
Buddhadeb Dawn
Gregg Rokosh
Qian-Hong Li
Roberto Bolli
Xian-Liang Tang
Yu-Ting Xuan
P2860
P2888
P304
P356
10.1007/S10741-007-9031-4
P577
2007-12-01T00:00:00Z